Let us not clap too loudly. The news that British scientists are spearheading the development of three new Ebola vaccines arrives with all the triumphalist bluster of a Victorian imperial bulletin. Yes, we are told, our boffins have once again stepped into the breach, ready to save the benighted tropics from the latest haemorrhagic scourge. But before we uncork the champagne, perhaps we should ask ourselves a tiresome but necessary question: why are we still here?
Ebola is not a new foe. It first announced itself to the world in 1976, and since then we have seen a depressing cycle of panic, temporary mobilisation, and then amnesia. The 2014-2016 West African outbreak killed over 11,000 people, and the global response was, to be charitable, chaotic. We threw money and personnel at the problem, but the infrastructure for vaccine development and deployment remained rudimentary. And now, years later, we are still in the “development” phase. The race is ongoing, but the track seems to stretch to infinity.
Do not misunderstand me: the science is admirable. The work being done at Oxford, Imperial College, and the London School of Hygiene and Tropical Medicine is world-class. These vaccines rely on advanced platforms: viral vectors, messenger RNA, and modified vaccinia Ankara. They may well offer broader protection and easier logistics than the existing Ervebo vaccine. But the key phrase is “may well”. We are yet again in the realm of hope, not certainty.
The deeper problem is structural. The pharmaceutical industry has little incentive to develop vaccines for diseases that primarily affect poor countries. Outbreaks are sporadic, and the market is unreliable. The only reason we have any progress at all is because of public funding and a sense of moral urgency that flares up only when bodies pile high on television screens. Once the outbreak subsides, so does the funding. We are, in effect, fighting a fire with a garden hose that is only turned on when the flames are visible from space.
And what of the intellectual property? Will these vaccines be available at cost to the nations that need them? Or will they be locked behind patents, available only to those who can pay? History offers a grim answer. The 2021 proposal at the World Trade Organization to waive patent protections for COVID-19 vaccines was fought tooth and nail by pharmaceutical companies. Why would Ebola be any different?
There is also a cultural dimension that the breathless headlines ignore. The West African outbreak was exacerbated by mistrust of foreign medical teams and government institutions. A vaccine is a biomedical tool, not a magic wand. Without community engagement, local health infrastructure, and political stability, even the best vaccine will fail. Yet the narrative remains one of white-coated saviours flying in to rescue helpless natives. This is not merely patronising; it is counterproductive.
The British scientists leading this effort deserve our respect, but they are operating within a system that is fundamentally broken. We have the technical capability to eliminate Ebola as a public health threat, but we lack the political will and the institutional imagination. The vaccine is the least of our problems. The real challenges are poverty, weak governance, and global inequality. These are not problems that can be jabbed away with a needle.
So yes, cheer the latest scientific advance. But remember that we have been here before. The race against the outbreak is not a sprint; it is a marathon run on a hamster wheel. Until we address the root causes, we will keep developing vaccines for diseases that should have been consigned to history decades ago. That is not progress. That is the tragedy of our age.
